1. Clinical Comparisons in CTEPH

2. Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Background

3. CTEPH Definitions From the International Prospective CTEPH Registry

4. Medical Therapy Riociguat Mechanism of Action

5. CHEST-1 Study Design

6. CHEST-1 Riociguat for the Treatment of CTEPH

7. CHEST-1 Subgroup Analysis Inoperable and Postoperative Patients

8. CHEST-1 Safety Results

9. MERIT-1 Study Design

10. MERIT-1 Primary Endpoint Results

11. MERIT-1 Primary Endpoint by Subgroup

12. MERIT-1 Secondary Endpoint 6MWD

13. MERIT-1 Safety

14. Clinical Trials in CTEPH

15. Clinical Trials in CTEPH Hemodynamic Results

16. Clinical Trials in CTEPH Functional Capacity Results

17. CTEPH Is Not Just a Clot Problem

18. Microvasculopathy Associated With Proximal Disease in CTEPH

19. Small Vessel Disease May Be a Major Contributor to Persistent/Residual PH

20. Targeted Pharmacological Therapies for PAH and Possibly CTEPH

21. CTEPH Treatment Algorithm

22. Sequential Treatment With Riociguat and BPA in Patients With Inoperable CTEPH

23. Treatment Response to Multimodality Approach

24. CTEPH Trials in Progress

25. CTEPH Management

26. Conclusion

27. Abbreviations

28. Abbreviations (cont)